Compare Medpace Holdings Inc (MEDP) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Nike Inc — how do they compare? Medpace Holdings Inc trades at $530 (market cap $15.08B), while Nike Inc trades at $42.97 (market cap $64.49B). The key difference: Nike Inc is far larger — about 4.3× Medpace Holdings Inc's market cap, and Nike Inc pays a 3.77% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | NKE | |
|---|---|---|
Market Cap | $15.08B | $64.49B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $79.24 |
52-Week Low | $308.88 | $40.75 |
Enterprise Value | $14.55B | $66.49B |
Volume | — | 8,887,180 |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nike (NKE) trades at $43.76, down 1.82% on the day, with a neutral technical signal and bullish moving averages. Recent earnings consistently beat expectations, with Q1 2026 EPS of $0.72 surpassing the $0.11 estimate. Revenue declined to $46.31B in 2025, while net income margin compressed to 6.7%. The stock holds a consensus analyst price target of $50.80, with 49% of analysts rating it a Buy. A dividend of $0.41 is scheduled for payment on July 1, 2026.
Nike's outlook is mixed: strong brand equity and earnings beats support upside potential, but revenue pressures and margin compression pose risks. Investors face trade-offs between valuation support and execution challenges in key markets like China. The stock's current discount to consensus target suggests cautious optimism amid turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
